Hansa Medical's Annual Report for 2015 is now available on the company’s website, www.hansamedical.com. The Annual Report is posted to shareholders and other stakeholders who specifically request it. For further information please contact the company by telephone +46 46-16 56 70 or e-mail info@hansamedical.com. The information in this press release is disclosed pursuant to the Swedish Securities Markets Act and/or the Swedish Financial Instruments Trading Act. The information was released for public disclosure on March 31, 2016 at 12.00 CET. For further information, please contact: Hansa Medical AB Göran Arvidson, CEO Mobile: 46 70-633 30 42 E-mail: goran.arvidson@hansamedical.com www.hansamedical.com About Hansa Medical AB Hansa Medical is a biopharmaceutical company focusing on novel immunomodulatory enzymes. The lead project IdeS is an antibody-degrading enzyme in clinical development, with potential use in transplantation and rare autoimmune diseases. Additional projects focus on development of new antibody modulating enzymes, as well as HBP, a diagnostic biomarker for prediction of severe sepsis at emergency departments that is already introduced on the market. The company is based in Lund, Sweden. Hansa Medical’s share (ticker: HMED) is listed on Nasdaq Stockholm.
Hansa Medical publishes the Annual Report for 2015
| Source: Hansa Medical AB
Attachments
